MEG3 and hepatocellular carcinoma: Braconi et al. [14] addressed the involvement of altered DNA methylation patterns at the DLK1-MEG3 locus indirectly by treating cells with the DNMT1 inhibitor aza-cytidine (resulting in MEG3 up-regulation in the HCC lines HepG2 and Huh-7 but not PLC/PRF-5) or knocking down DNMT1 and DNMT3b using an siRNA approach (resulting in a 1.5-fold induction of expression in HepG2 cells).